uniQure Provides Positive Recommendation to Advance P- I/II Study of AMT-130 for Huntington Disease

 uniQure Provides Positive Recommendation to Advance P- I/II Study of AMT-130 for Huntington Disease

uniQure Provides Positive Recommendation to Advance P- I/II Study of AMT-130 for Huntington Disease

Shots:

  • The DSMB recommended continued the dosing in the P- I/II clinical trial assessing AMT-130 in patients with a second higher-dose cohort, after review safety data from the first cohort of ten patients
  • The first cohort of P- I/II trial for AMT-130 in 10 patients out of which six patients received treatment with AMT-130 and four patients received imitation surgery for early manifest HD. UniQure will now begin to enroll patients in the higher-dose cohort of the trial
  • The company initiates clinical development of the therapy in Europe in H2’21 and share initial imaging and biomarker data from the US clinical trial in 2021

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: STAT News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post